Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 25/100

Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – SKYE

Key Takeaway: Levi & Korsinsky has notified investors of a class action lawsuit against Skye Bioscience, Inc. concerning alleged securities fraud occurring between November 2024 and October 2025. The lawsuit claims that the company's lead product candidate, nimacimab, was misrepresented in terms of its effectiveness and commercial prospects. Investors who suffered losses during this period have until January 16, 2026, to seek lead plaintiff status, but compensation can be claimed without this status. The law firm emphasizes no costs for affected investors to participate in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges that the company's lead product candidate, nimacimab, was less effective than previously communicated.
  • The prospects of nimacimab's clinical, regulatory, and commercial success were reportedly overstated.
  • The defendants' public statements about the product and company were materially false and misleading.
  • Investors affected by the alleged securities fraud may face financial losses.

Full Press Release Details

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team:
SKYE investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i)The Company’s lead product candidate, nimacimab, was less effective than defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Skye Bioscience, Inc. during the relevant time frame, you have until January 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit about Skye Bioscience?

The lawsuit aims to recover losses for Skye Bioscience investors due to alleged securities fraud.

Who can participate in the Skye Bioscience lawsuit?

Investors affected by false statements from November 4, 2024, to October 3, 2025, can participate.

How can I join the class action for Skye Bioscience?

You can request to be appointed as lead plaintiff by January 16, 2026.

Will it cost me to participate in the lawsuit?

No, there are no out-of-pocket costs or fees to participate as a class member.

Why choose Levi & Korsinsky for this lawsuit?

Levi & Korsinsky has a proven track record in securities litigation, securing significant recoveries.

Last updated: Dec 4, 2025